Cait E. Hamele

Cait E. Hamele

Auto-generated profile, based on publicly available information

Cait E. Hamele

Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2022 in Science Signaling
Verified
Journal Article
Open access
TYTomer M. Yaron
Tomer M. Yaron
BHBrook E. Heaton
Brook E. Heaton
TLTyler M. Levy
Tyler M. Levy
JJJared L. Johnson
Jared L. Johnson
TJTristan X. Jordan
Tristan X. Jordan
NHNicholas Heaton
Nicholas Heaton
Multiple coronaviruses have emerged independently in the past 20 years that cause lethal human diseases. Although vaccine development targeting these viruses has been accelerated substantially, there remain patients requiring treatment who cannot be vaccinated or who experience breakthrough infections. Understanding the common host factors necessary for the life cycles of coronaviruses may reveal conserved therapeutic targets. Here, we used the known substrate specificities of mammalian protein kinases to deconvolute the sequence of phosphorylation events mediated by three host protein kinase families (SRPK, GSK-3, and CK1) that coordinately phosphorylate a cluster of serine and threonine residues in the viral N protein, which is required for viral replication. We also showed that loss or inhibition of SRPK1/2, which we propose initiates the N protein phosphorylation cascade, compromised the viral replication cycle. Because these phosphorylation sites are highly conserved across coronaviruses, inhibitors of these protein kinases not only may have therapeutic potential against COVID-19 but also may be broadly useful against coronavirus-mediated diseases.

19 May 2022 in Blood
Verified
Journal Article
Open access
PDF file
HCHeeJin Cheon
HeeJin Cheon
JXJeffrey C. Xing
Jeffrey C. Xing
KMKatharine B. Moosic
Katharine B. Moosic
JUJohnson Ung
Johnson Ung
VCVivian W. Chan
Vivian W. Chan
TLThomas P. Loughran
Thomas P. Loughran
Large granular lymphocyte (LGL) leukemia comprises a group of rare lymphoproliferative disorders whose molecular landscape is incompletely defined. We leveraged paired whole-exome and transcriptome sequencing in the largest LGL leukemia cohort to date, which included 105 patients (93 T-cell receptor αβ [TCRαβ] T-LGL and 12 TCRγδ T-LGL). Seventy-six mutations were observed in 3 or more patients in the cohort, and out of those, STAT3, KMT2D, PIK3R1, TTN, EYS, and SULF1 mutations were shared between both subtypes. We identified ARHGAP25, ABCC9, PCDHA11, SULF1, SLC6A15, DDX59, DNMT3A, FAS, KDM6A, KMT2D, PIK3R1, STAT3, STAT5B, TET2, and TNFAIP3 as recurrently mutated putative drivers using an unbiased driver analysis approach leveraging our whole-exome cohort. Hotspot mutations in STAT3, PIK3R1, and FAS were detected, whereas truncating mutations in epigenetic modifying enzymes such as KMT2D and TET2 were observed. Moreover, STAT3 mutations co-occurred with mutations in chromatin and epigenetic modifying genes, especially KMT2D and SETD1B (P < .01 and P < .05, respectively). STAT3 was mutated in 50.5% of the patients. Most common Y640F STAT3 mutation was associated with lower absolute neutrophil count values, and N647I mutation was associated with lower hemoglobin values. Somatic activating mutations (Q160P, D170Y, L287F) in the STAT3 coiled-coil domain were characterized. STAT3-mutant patients exhibited increased mutational burden and enrichment of a mutational signature associated with increased spontaneous deamination of 5-methylcytosine. Finally, gene expression analysis revealed enrichment of interferon-γ signaling and decreased phosphatidylinositol 3-kinase–Akt signaling for STAT3-mutant patients. These findings highlight the clinical and molecular heterogeneity of this rare disorder.

30 March 2021 in Blood
Verified
Journal Article
Open access
PDF file
TOThomas L. Olson
Thomas L. Olson
HCHeeJin Cheon
HeeJin Cheon
JXJeffrey C. Xing
Jeffrey C. Xing
KOKristine C. Olson
Kristine C. Olson
UPUmadevi Paila
Umadevi Paila
TLThomas P. Loughran
Thomas P. Loughran
Chronic natural killer large granular lymphocyte (NK-LGL) leukemia, also referred to as chronic lymphoproliferative disorder of NK cells, is a rare disorder defined by prolonged expansion of clonal NK cells. Similar prevalence of STAT3 mutations in chronic T-LGL and NK-LGL leukemia is suggestive of common pathogenesis. We undertook whole-genome sequencing to identify mutations unique to NK-LGL leukemia. The results were analyzed to develop a resequencing panel that was applied to 58 patients. Phosphatidylinositol 3-kinase pathway gene mutations (PIK3CD/PIK3AP1) and TNFAIP3 mutations were seen in 5% and 10% of patients, respectively. TET2 was exceptional in that mutations were present in 16 (28%) of 58 patient samples, with evidence that TET2 mutations can be dominant and exclusive to the NK compartment. Reduced-representation bisulfite sequencing revealed that methylation patterns were significantly altered in TET2 mutant samples. The promoter of TET2 and that of PTPRD, a negative regulator of STAT3, were found to be methylated in additional cohort samples, largely confined to the TET2 mutant group. Mutations in STAT3 were observed in 19 (33%) of 58 patient samples, 7 of which had concurrent TET2 mutations. Thrombocytopenia and resistance to immunosuppressive agents were uniquely observed in those patients with only TET2 mutation (Games-Howell post hoc test, P = .0074; Fisher’s exact test, P = .00466). Patients with STAT3 mutation, inclusive of those with TET2 comutation, had lower hematocrit, hemoglobin, and absolute neutrophil count compared with STAT3 wild-type patients (Welch’s t test, P ≤ .015). We present the discovery of TET2 mutations in chronic NK-LGL leukemia and evidence that it identifies a unique molecular subtype.

23 October 2018 in Leukemia
Verified
Journal Article
Closed access
PDF file
TWT. Tiffany Wang
T. Tiffany Wang
JYJun Yang
Jun Yang
YZYong Zhang
Yong Zhang
MZMeili Zhang
Meili Zhang
SDSigrid Dubois
Sigrid Dubois
TLThomas P. Loughran
Thomas P. Loughran

26 April 2018 in Blood
Verified
Journal Article
Open access
PDF file
JYJun Yang
Jun Yang
FLFrancis R. LeBlanc
Francis R. LeBlanc
SDShubha A. Dighe
Shubha A. Dighe
CHCait E. Hamele
Cait E. Hamele
TOThomas L. Olson
Thomas L. Olson
TLThomas P. Loughran
Thomas P. Loughran
Key Points: TRAIL is upregulated in LGL leukemia and TRAIL-DcR2 signaling drives constitutive activation of NF-κB. Proteasome inhibitors (bortezomib and ixazomib) effectively interrupt TRAIL-induced activation of NF-κB and induce apoptosis.

27 July 2022 in Journal of Virology
Verified
Journal Article
Closed access
CHCait E. Hamele
Cait E. Hamele
ARAlistair B. Russell
Alistair B. Russell
NHNicholas Heaton
Nicholas Heaton
Influenza A virus poses a significant threat to public health, and each year, millions of people in the United States alone are exposed to the virus. We do not currently, however, fully understand why some individuals clear the infection asymptomatically and others become severely ill.